Nasdaq · CIK 0001176309
ORMP ORAMED PHARMACEUTICALS INC.
Insider trading from SEC Form 4. Last filing 9 d ago. Close $4.33 on Oct 9, 2026, +112% from the 52-week low and -19% from the high.
Last 90 days
Net insider value
-$226k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
2
$226k by 2 insiders
Insiders on file
4
with a Form 4 at this company
Price and insider trades, last year
ORMPOct 9, 2026 · close 4.33
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at ORAMED PHARMACEUTICALS INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 19Weak | Avraham Gabay Chief Financial Officer sell | $90k 20,000 shares | -2% | +119% from low · -16% from high | |
| 19Weak | Joshua Hexter COO & CBO sell | $135k 30,000 shares | -2% | +119% from low · -16% from high |
Congressional trades
1 trade in ORMP disclosed by members of Congress under the STOCK Act. All congressional trades.
| Member | Trade | Asset | Reported range | Trade / filing date | Source |
|---|---|---|---|---|---|
Brad Knott House · R-NC | Sale | ORMP Oramed Pharmaceuticals Inc. - Common Stock | $15k to $50k | Jan 10, 2025 / Feb 25, 2025 46 days after the trade | Clerk |
Transactions
The last 43 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Joshua Hexter COO & CBO | SOpen-market sale Common Stock10b5-1 | -30,000 | $4.51 | $135k | 1,328,130 | 9 d ago |
| Oct 1, 2026 | Avraham Gabay Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -20,000 | $4.51 | $90k | 861,076 | 9 d ago |
| Sep 24, 2026 | Avraham Gabay Chief Financial Officer | AGrant or award Common Stock | +209,291 | - | - | 881,076 | 16 d ago |
| Sep 24, 2026 | Joshua Hexter COO & CBO | AGrant or award Common Stock | +75,455 | - | - | 1,148,839 | 16 d ago |
| Sep 24, 2026 | Miriam Kidron Chief Scientific Officer | AGrant or award Common Stock | +208,125 | - | - | 1,341,263 | 16 d ago |
| Sep 24, 2026 | Nadav Kidron President and CEO | AGrant or award Common Stock | +349,497 | - | - | 3,771,740 | 16 d ago |
| Sep 24, 2026 | Miriam Kidron Chief Scientific Officer | AGrant or award Common Stock | +209,291 | - | - | 1,550,554 | 16 d ago |
| Sep 24, 2026 | Nadav Kidron President and CEO | AGrant or award Common Stock | +368,765 | - | - | 4,140,505 | 16 d ago |
| Sep 24, 2026 | Joshua Hexter COO & CBO | AGrant or award Common Stock | +209,291 | - | - | 1,358,130 | 16 d ago |
| Sep 24, 2026 | Joshua Hexter COO & CBO | DDisposition to issuer Stock option (right to buy)derivative | -50,000 | - | - | 0 | 16 d ago |
| Sep 24, 2026 | Miriam Kidron Chief Scientific Officer | DDisposition to issuer Stock option (right to buy)derivative | -104,000 | - | - | 0 | 16 d ago |
| Sep 24, 2026 | Joshua Hexter COO & CBO | DDisposition to issuer Stock option (right to buy)derivative | -50,000 | - | - | 0 | 16 d ago |
| Sep 24, 2026 | Nadav Kidron President and CEO | DDisposition to issuer Stock option (right to buy)derivative | -196,500 | - | - | 0 | 16 d ago |
| Sep 24, 2026 | Miriam Kidron Chief Scientific Officer | DDisposition to issuer Stock option (right to buy)derivative | -100,000 | - | - | 0 | 16 d ago |
| Sep 24, 2026 | Joshua Hexter COO & CBO | DDisposition to issuer Stock option (right to buy)derivative | -36,000 | - | - | 0 | 16 d ago |
| Sep 24, 2026 | Nadav Kidron President and CEO | DDisposition to issuer Stock option (right to buy)derivative | -190,000 | - | - | 0 | 16 d ago |
| Sep 24, 2026 | Miriam Kidron Chief Scientific Officer | DDisposition to issuer Stock option (right to buy)derivative | -69,999 | - | - | 0 | 16 d ago |
| Sep 24, 2026 | Miriam Kidron Chief Scientific Officer | DDisposition to issuer Stock option (right to buy)derivative | -47,000 | - | - | 0 | 16 d ago |
| Sep 24, 2026 | Nadav Kidron President and CEO | DDisposition to issuer Stock option (right to buy)derivative | -49,000 | - | - | 0 | 16 d ago |
| Sep 24, 2026 | Nadav Kidron President and CEO | DDisposition to issuer Stock option (right to buy)derivative | -97,000 | - | - | 0 | 16 d ago |
| Sep 24, 2026 | Miriam Kidron Chief Scientific Officer | DDisposition to issuer Stock option (right to buy)derivative | -100,000 | - | - | 0 | 16 d ago |
| Sep 24, 2026 | Nadav Kidron President and CEO | DDisposition to issuer Stock option (right to buy)derivative | -150,000 | - | - | 0 | 16 d ago |
| Sep 24, 2026 | Miriam Kidron Chief Scientific Officer | DDisposition to issuer Stock option (right to buy)derivative | -72,000 | - | - | 0 | 16 d ago |
| Sep 24, 2026 | Nadav Kidron President and CEO | DDisposition to issuer Stock option (right to buy)derivative | -107,000 | - | - | 0 | 16 d ago |
| Feb 11, 2025 | Avraham Gabay Chief Financial Officer | AGrant or award Common Stock | +34,000 | $0.00 | $0 | 392,040 | Feb 11, 2025 |
| Feb 11, 2025 | Joshua Hexter COO & CBO | AGrant or award Common Stock | +45,000 | $0.00 | $0 | 751,333 | Feb 11, 2025 |
| Feb 11, 2025 | Miriam Kidron Chief Scientific Officer | AGrant or award Common Stock | +74,000 | $0.00 | $0 | 1,074,666 | Feb 11, 2025 |
| Feb 11, 2025 | Nadav Kidron President and CEO | AGrant or award Common Stock | +141,000 | $0.00 | $0 | 2,400,598 | Feb 11, 2025 |
| Feb 11, 2025 | Nadav Kidron President and CEO | AGrant or award Common Stock | +186,000 | $0.00 | $0 | 2,586,598 | Feb 11, 2025 |
| Feb 11, 2025 | Miriam Kidron Chief Scientific Officer | AGrant or award Common Stock | +52,000 | $0.00 | $0 | 1,126,666 | Feb 11, 2025 |
| Feb 11, 2025 | Joshua Hexter COO & CBO | AGrant or award Common Stock | +48,500 | $0.00 | $0 | 799,833 | Feb 11, 2025 |
| Feb 11, 2025 | Avraham Gabay Chief Financial Officer | AGrant or award Common Stock | +42,000 | $0.00 | $0 | 434,040 | Feb 11, 2025 |
| Feb 11, 2025 | Joshua Hexter COO & CBO | AGrant or award Common Stock | +33,334 | $0.00 | $0 | 833,167 | Feb 11, 2025 |
| Feb 11, 2025 | Nadav Kidron President and CEO | AGrant or award Common Stock | +100,000 | $0.00 | $0 | 2,686,598 | Feb 11, 2025 |
| Feb 11, 2025 | Miriam Kidron Chief Scientific Officer | AGrant or award Common Stock | +66,667 | $0.00 | $0 | 1,193,333 | Feb 11, 2025 |
| Jan 2, 2025 | Avraham Gabay Chief Financial Officer | AGrant or award Common Stock | +188,000 | - | - | 358,040 | Jan 6, 2025 |
| Jan 2, 2025 | Joshua Hexter COO & CBO | AGrant or award Common Stock | +194,500 | - | - | 706,333 | Jan 6, 2025 |
| Jan 2, 2025 | Nadav Kidron President and CEO | AGrant or award Common Stock | +433,500 | - | - | 2,259,598 | Jan 6, 2025 |
| Jan 2, 2025 | Miriam Kidron Chief Scientific Officer | AGrant or award Common Stock | +207,000 | - | - | 1,000,666 | Jan 6, 2025 |
| Nov 7, 2024 | Avraham Gabay Chief Financial Officer | AGrant or award Common Stock | +30,000 | - | - | 170,040 | Nov 8, 2024 |
| Nov 7, 2024 | Joshua Hexter COO & CBO | AGrant or award Common Stock | +30,000 | - | - | 511,833 | Nov 8, 2024 |
| Nov 7, 2024 | Nadav Kidron President and CEO | AGrant or award Common Stock | +45,000 | - | - | 1,826,098 | Nov 8, 2024 |
| Nov 7, 2024 | Miriam Kidron Chief Scientific Officer | AGrant or award Common Stock | +30,000 | - | - | 793,666 | Nov 8, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Avraham GabayChief Financial Officer
- Joshua HexterCOO & CBO
- Nadav KidronPresident and CEO
- Miriam KidronChief Scientific Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.